Credit Suisse Ag Trevena Inc Transaction History

Credit Suisse Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.2 - $0.5 $2,213 - $5,534	-11,069 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.41 - $0.63 $2,042 - $3,138	-4,981 Reduced 31.03%	11,069 $6,000
Q4 2021 Feb 14, 2022	BUY	$0.57 - $1.29 $9,148 - $20,704	16,050 New	16,050 $9,000
Q2 2021 Aug 16, 2021	SELL	$1.46 - $2.25 $24,364 - $37,548	-16,688 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$1.77 - $2.93 $29,537 - $48,895	16,688 New	16,688 $30,000
Q2 2018 Aug 14, 2018	SELL	$1.44 - $2.24 $31,063 - $48,321	-21,572 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$1.51 - $2.06 $7,463 - $10,182	4,943 Added 29.73%	21,572 $36,000
Q4 2017 Feb 14, 2018	SELL	$1.4 - $2.6 $38,827 - $72,108	-27,734 Reduced 62.52%	16,629 $26,000
Q3 2017 Nov 14, 2017	BUY	$2.22 - $2.79 $61,651 - $77,481	27,771 Added 167.38%	44,363 $113,000
Q2 2017 Aug 14, 2017	BUY	N/A	16,592	16,592 $38,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $273M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.